Aspect Biosystems announced today that it entered into a partnership with the Juvenile Diabetes Research Foundation (JDRF). The partnership will support Aspect’s focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chronic immune suppression. Vancouver, British Columbia-based Aspect said […]
Juvenile Diabetes Research Foundation (JDRF)
FDA approves ready-to-use liquid glucagon from Xeris
Xeris Pharmaceuticals (NSDQ:XERS) said yesterday that the FDA has approved its Gvoke glucagon injection for the treatment of hypoglycemia. Gvoke is a ready-to-use, room-temperature, stable liquid glucagon designed to treat severe hypoglycemia in pediatric and adult patients with Type 1 diabetes aged two years old or above. Chicago-based Xeris’ Gvoke may be administered with a pre-filled […]
Researchers tout use of closed-loop insulin delivery system
At this year’s meeting of the European Association for the Study of Diabetes, researchers reported that use of a hybrid day-night closed-loop insulin delivery system is better than sensor-augmented pump therapy for blood sugar control in people with poorly controlled Type 1 diabetes. The JDRF-funded study included 44 men and 42 women with Type 1 […]
SFC Fluidics lands JDRF support for interoperable insulin patch pump
SFC Fluidics said today that it inked a deal with JDRF to support the development of an insulin patch pump with open-protocol communication features. SFC Fluidics plans to use the two-year funding deal from JDRF to speed up the development of a patch pump that securely connects with other devices, like a continuous glucose monitor […]
JDRF tackles insulin consistency, potency at U.S. pharmacies
JDRF is teaming up with the American Diabetes Association and the Leona M. and Harry B. Helmsley Charitable Trust to support research evaluating the consistency and potency of insulin purchased at retail pharmacies in the U.S. The group called for proposals from analytical laboratories to assess the activity of insulin in vials and cartridges, looking […]
Congress doles out $300m to fund diabetes research
Congress today approved a two-year extension of the Special Diabetes Program, giving the National Institutes of Health $300 million to fund research into new therapies and technologies for people with Type I diabetes. The program, which has historically garnered bipartisan support, was last reauthorized in 2015 when lawmakers budgeted $150 million over two years for […]
Cam Med partners with JDRF to develop flexible, bandage-like insulin patch pump
Medical device startup Cam Med has partnered with JDRF to develop an ultra-thin, flexible insulin patch pump to be used with next-generation artificial pancreas systems. The goal of the partnership is to speed up the development of Cam Med’s Evopump – a conformable, disposable patch pump – so that the device can be integrated into […]
Report: Advocacy groups urge Congress to fund diabetes research programs
Advocacy groups have reportedly warned Congress that if lawmakers don’t find permanent funding solutions for diabetes research programs, it could jeopardize important work being done around the country to help people living with diabetes. Politicians on Capitol Hill have provided funding that will support the Special Diabetes Program and the Special Diabetes Program for Indians through […]
SFC Fluidics inks deal with JDRF to develop automated insulin delivery system
SFC Fluidics has inked a two-year deal with JDRF to develop an automated insulin delivery system that combines a continuous glucose monitor and an insulin delivery algorithm into a single disposable device. JDRF is slated to provide funding to the medical device company as part of its Artificial Pancreas Project, which aims to accelerate the […]
Semma Therapeutics closes $114m round to advance cell therapy for Type I diabetes
Semma Therapeutics has closed an oversubscribed $114 million Series B round to help fund the development of its encapsulated stem cell-derived islet therapy for Type I diabetes. The Cambridge, Mass.-based company reported that it plans to use the newly-acquired funds to bring its cell therapy through clinical proof-of-concept studies, as well as explore other regenerative […]
